Biogen (MA, USA) and Eisai Co. (Tokyo, Japan) have announced plans to pursue regulatory approval…
Browsing: Alzheimer’s disease
Four studies presented at SfN Neuroscience have demonstrated how the microbiome interacts with the brain in mice, revealing the possible mechanisms behind gut–brain communication.
Abstracts presented at SfN Neuroscience 2019 provide insight into how gene therapy advancements could be used treat diseases such as Parkinson’s and Alzheimer’s in the future.
SfN19: Metabolic disturbances in the brain may exacerbate and forewarn Alzheimer’s pathology in mice
Abstracts presented at SfN Neuroscience 2019 have revealed that metabolic disturbances in the brain could exacerbate and forewarn Alzheimer’s pathology in mice.
In a recent follow-up study, researchers discovered that when used as a dietary supplement, choline was able to reduce symptoms associated with Alzheimer’s disease in female mice.
What are the main challenges surrounding primary prevention trials for Alzheimer’s? Should researchers be exploring alternative avenues to amyloid-β in these trials? Take a look at our interview with Randall Bateman to find out more.
This week in industry includes trials on elenbecestat to be discontinued, ofatumumab demonstrating superiority to Aubagio and the Toca 5 trial results failing to meet primary endpoint.
Genetic therapies represent a remarkable avenue for potentially slowing and preventing neurodegenerative diseases. This includes a first-in-human, gene-silencing treatment for Alzheimer’s disease. Find out more on this from Catherine Mummery.
In this video, we spoke with Henrik Zetterberg to find out how challenges with replication, reproducibility and specificity could be addressed in the field.
A blood test to diagnose individuals at risk of developing Alzheimer’s disease before symptoms arise may be closer to reality, as researchers report a 94% accuracy in recent findings.